The stock price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has plunged by -2.77 when compared to previous closing price of 8.66, but the company has seen a 14.56% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-11 that Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity.
Is It Worth Investing in Adaptive Biotechnologies Corp (NASDAQ: ADPT) Right Now?
The stock has a 36-month beta value of 1.70. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 4 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ADPT is 141.74M, and at present, short sellers hold a 6.11% of that float. On March 26, 2025, the average trading volume of ADPT was 1.70M shares.
ADPT’s Market Performance
ADPT stock saw a decrease of 14.56% in the past week, with a monthly decline of 0.00% and a quarterly a decrease of 40.33%. The volatility ratio for the week is 7.88%, and the volatility levels for the last 30 days are 9.62% for Adaptive Biotechnologies Corp (ADPT). The simple moving average for the last 20 days is 7.91% for ADPT stock, with a simple moving average of 50.97% for the last 200 days.
Analysts’ Opinion of ADPT
Many brokerage firms have already submitted their reports for ADPT stocks, with Goldman repeating the rating for ADPT by listing it as a “Buy.” The predicted price for ADPT in the upcoming period, according to Goldman is $9 based on the research report published on March 21, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $15. The rating they have provided for ADPT stocks is “Overweight” according to the report published on July 05th, 2023.
Scotiabank gave a rating of “Sector Outperform” to ADPT, setting the target price at $15 in the report published on January 05th of the previous year.
ADPT Trading at 8.27% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.55% of loss for the given period.
Volatility was left at 9.62%, however, over the last 30 days, the volatility rate increased by 7.88%. Over the last 50 days, in opposition, the stock is trading +29.54% upper at present.
During the last 5 trading sessions, ADPT rose by +14.56%, which changed the moving average for the period of 200-days by +119.27% in comparison to the 20-day moving average, which settled at $7.80. In addition, Adaptive Biotechnologies Corp saw 40.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADPT starting from Harlan Robins, who proposed sale 1,698 shares at the price of $8.66 back on Mar 24 ’25. After this action, Harlan Robins now owns shares of Adaptive Biotechnologies Corp, valued at $14,705 using the latest closing price.
GRIFFIN MICHELLE RENEE, the Director of Adaptive Biotechnologies Corp, sale 36,291 shares at $7.19 during a trade that took place back on Mar 13 ’25, which means that GRIFFIN MICHELLE RENEE is holding 15,394 shares at $260,932 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -0.86 for the present operating margin
- 0.58 for the gross margin
The net margin for Adaptive Biotechnologies Corp stands at -0.89. The total capital return value is set at -0.35. Equity return is now at value -62.41, with -26.57 for asset returns.
Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.07. The debt to equity ratio resting at 0.44. The interest coverage ratio of the stock is -13.36.
Currently, EBITDA for the company is -128.76 million with net debt to EBITDA at -0.32. When we switch over and look at the enterprise to sales, we see a ratio of 7.22. The receivables turnover for the company is 4.29for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
To sum up, Adaptive Biotechnologies Corp (ADPT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
